| Milestone | Estimated Timeline (2026‑2030) | Critical Success Factors | |-----------|--------------------------------|---------------------------| | (GLP 28‑day and 90‑day studies) | Q4 2026 – Q2 2027 | Completion of Good Laboratory Practice (GLP) studies, formulation development. | | Investigational New Drug (IND) filing (US FDA) | Mid‑2027 | Submission of pre‑clinical PK/PD, safety data, CMC package. | | Phase I (First‑in‑Human) – Single ascending dose (SAD) & multiple ascending dose (MAD) in healthy volunteers | Late 2027 – Early 2028 | Demonstration of safety, tolerability, and dose‑proportional exposure. | | Phase Ib (dose‑finding in patients) – B‑cell malignancies (e.g., relapsed/refractory CLL, DLBCL) | 2028‑2029 | Biomarker (p‑AKT) modulation; early efficacy signals. | | Phase II (proof‑of‑concept) – Selected indications (CLL, indolent NHL) | 2029‑2030 | Achievement of ≥30 % overall response rate (ORR) with acceptable safety. | | Potential partnership / out‑licensing | Throughout 2027‑2029 | Strong IP, clean safety profile, and differentiated efficacy. |
But it wasn't a recording. The Elias on the screen was younger, wearing the clothes Elias had worn ten years ago—the day of the Grid Outage. But there was something wrong. The Elias on the screen was calm, too calm. He wasn't looking at the camera with fear; he was looking with recognition. ppv-1780072
00:00:03... 00:00:02... 00:00:01...
PPP-1780072, also referred to as "Catalyst," is a type of cybersecurity threat that has been associated with an array of malicious activities. It is believed to be linked to a sophisticated hacking group, with roots in Eastern Europe, that has been conducting coordinated cyber attacks against governments, financial institutions, and critical infrastructure across the world. | Milestone | Estimated Timeline (2026‑2030) | Critical
Once inside the network, the attackers typically use various exploits to gain elevated privileges and pivot to critical systems. They then deploy malware, specifically designed to evade detection by traditional security software, to remain entrenched within the compromised system. | | Phase Ib (dose‑finding in patients) –